Nanotechnology in Cancer Treatment Market Report 2026

The nanotechnology in cancer treatment market size has grown rapidly in recent years. It will grow from $159.07 billion in 2025 to $183.23 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, advancements in nanomaterial engineering, expansion of oncology research funding, growing collaboration between pharma and research institutions, early clinical success of nano-based therapies.

The nanotechnology in cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $319.04 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing adoption of personalized cancer treatment approaches, rising investments in nanomedicine research, expansion of clinical trials using nanotechnology, growing focus on minimally invasive cancer therapies, advancements in nano-enabled diagnostics. Major trends in the forecast period include increasing development of nanoparticle-based drug delivery systems, rising adoption of targeted cancer therapies, growing use of multifunctional nanomaterials, expansion of personalized oncology treatments, enhanced focus on reducing chemotherapy side effects.

The increasing demand for targeted therapies is expected to drive the growth of the nanotechnology in cancer treatment market in the coming years. Targeted therapies are cancer treatments designed to specifically act on molecular markers or pathways associated with tumor growth and progression. The rising demand for these therapies is attributed to their capability to accurately target cancer cells, thereby limiting damage to healthy tissues and reducing side effects. Nanotechnology in cancer treatment supports targeted therapies by facilitating precise drug delivery directly to cancer cells, enhancing therapeutic effectiveness while minimizing harm to healthy tissues. For example, in July 2023, according to a report published by the American Society of Gene & Cell Therapy (ASGCT), at the end of Q1 2023 there were 247 gene therapies in Phase II, and this figure increased by 5% to reach 260 by the end of Q2 2023. Thus, the growing demand for targeted therapies is contributing to the expansion of the nanotechnology in cancer treatment market.

Major companies operating in the nanotechnology in cancer treatment market are concentrating on the development of advanced solutions such as immunotherapy nano formulations to improve immune system targeting and reduce adverse effects in cancer patients. Immunotherapy nano formulation involves the use of nanotechnology to deliver immune-based therapies directly to target sites, improving treatment precision while enhancing drug stability, bioavailability, and activation of immune responses. For instance, in December 2023, Cello Therapeutics launched CE120, a broad-spectrum therapeutic cancer nano vaccine that received clearance from the Food and Drug Administration. This therapy represents the first clinical application of platelet membrane-coated nanoparticles for the treatment of solid tumors. CE120 integrates targeted drug delivery with immune system activation, with the goal of eliminating tumors and preventing recurrence. Its innovative nanotechnology platform improves both therapeutic accuracy and immune response, positioning CE120 as a groundbreaking nanomedicine in cancer care.

In March 2023, Sona Nanotech Inc., a Canada-based company providing nanotechnology solutions for cancer treatment, acquired Siva Therapeutics Inc. for $2 million. Through this acquisition, Sona Nanotech aims to expand its presence in cancer therapeutics by developing gold nanorod-based targeted hyperthermia treatments for solid tumors, supporting its objective of advancing nanotechnology-driven cancer therapies. Siva Therapeutics Inc. is a US-based company focused on developing nanotechnology-based cancer treatments through its targeted hyperthermia therapy (THT) platform.

Major companies operating in the nanotechnology in cancer treatment market are Pfizer Inc., AstraZeneca PLC, Novartis AG, Amgen Inc., GE Healthcare Technologies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Arrowhead Pharmaceuticals Inc., Nanobiotix S.A., EnGeneIC Ltd., Nanospectra Biosciences Inc., Sona Nanotech Inc., Immix Biopharma Inc., DNA Nanobots LLC, Nanovery Limited, CytImmune Sciences Inc., NanOlogy LLC, NanoApps Medical Inc., Selecta Biosciences Inc., Bind Therapeutics Inc., BlueWillow Biologics Inc., Nanobiomed Inc.

North America was the largest region in the nanotechnology in cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanotechnology in cancer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanotechnology in cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the nanotechnology in cancer treatment market by increasing costs of imported nanomaterials, specialized laboratory equipment, precision manufacturing tools, and analytical instruments required for nano-based drug development. Pharmaceutical and research organizations in North America and Europe are most affected due to reliance on imported high-precision components, while Asia-Pacific faces higher production and export costs. These tariffs are increasing development expenses and extending research timelines. However, they are also encouraging domestic nanomaterial production, regional research collaboration, and investment in localized nanotechnology manufacturing capabilities.

The nanotechnology in cancer treatment market research report is one of a series of new reports that provides nanotechnology in cancer treatment market statistics, including nanotechnology in cancer treatment industry global market size, regional shares, competitors with a nanotechnology in cancer treatment market share, detailed nanotechnology in cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nanotechnology in cancer treatment industry. This nanotechnology in cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanotechnology in cancer treatment involves the use of nanoscale materials and tools to improve cancer diagnosis, monitoring, and therapy. It enables accurate drug delivery to cancer cells, minimizing damage to surrounding healthy tissues. This approach seeks to enhance treatment efficiency, reduce side effects, and support personalized medicine approaches.

The primary types of nanotechnology in cancer treatment include liposomes, dendrimers, and nanoparticles. Liposomes are small spherical vesicles composed of lipid bilayers that are used to deliver drugs directly to targeted cells within the body. The treatment types comprise chemotherapy, immunotherapy, targeted therapy, combined therapy approaches, and surgical assistance and are applied across various cancer types, including breast cancer, lung cancer, prostate cancer, colorectal cancer, blood cancer, and others. These are utilized in multiple applications, such as targeted drug delivery, photothermal therapy, radiation therapy enhancement, diagnostics and imaging, and gene delivery systems, as well as by various end users including hospitals, research institutions, diagnostic laboratories, pharmaceutical companies, and contract research organizations (CROs).

The nanotechnology in cancer treatment market consists of revenues earned by entities by providing services such as hyperthermia therapy services, multi-drug co-delivery services, and immune checkpoint modulation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanotechnology in cancer treatment market also includes sales of magnetic nanoparticles, carbon nanotubes, polymeric nanoparticles, and quantum dots. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.